PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC)
Clinical trials for PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC) explained in plain language.
Never miss a new study
Get alerted when new PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC) trials appear
Sign up with your email to follow new studies for PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat pancreatic cancer: combo therapy targets genetic weak spot
Disease control Recruiting nowThis study tests a combination of two drugs—cemiplimab (an immunotherapy) and gemcitabine (a standard chemo)—in people with advanced pancreatic cancer that has a specific genetic change (SWI/SNF). The goal is to see if this combo helps patients live longer. About 43 adults who ha…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC)
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 12, 2026 12:05 UTC
-
New hope for Hard-to-Treat cancers: first human trial launches
Disease control Recruiting nowThis early-stage trial tests a new drug called DA 3501 in people with advanced stomach or pancreatic cancers that have a specific marker (CLDN18.2). The main goals are to find the safest dose and see if the drug can shrink tumors. About 51 adults will receive the drug every three…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC)
Phase: PHASE1 • Sponsor: Dong-A ST Co., Ltd. • Aim: Disease control
Last updated Jun 05, 2026 12:07 UTC
-
Blood marker may forecast deadly pancreatic surgery complications
Knowledge-focused Recruiting nowThis study looks at whether a blood marker called mHLA-DR can help doctors predict severe complications after pancreatic surgery. About 100 people having this surgery will be followed. The goal is to find an early warning sign for problems like infection or pancreatic leaks.
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC)
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 09, 2026 12:10 UTC